Net Loss: ($14.7M) (-63.3%); Loss Per Share: ($0.35) (+36.4%).
2018 & 2019 Anticipated Goals and Milestones: BIVIGAM PDUFA target action date is October 25.
Respond to complete response letter and resubmit BLA for RI-002.
Obtain FDA approval for 3rd plasma collection center.
Commercial and promotional launch for RI-002.
Expand promotional activities for Nabi-HB.
Subscribe for full text news in your inbox